Clinical Research: Could Psychedelic Therapy Help Treat Eating Disorders?
Last reviewed and updated: June 17, 2026.
Key Takeaways
| Research status | Phase 1/2 pilot trials at Imperial College London and Johns Hopkins — early promising results, not yet established treatment |
| Primary target | Anorexia nervosa (psilocybin), bulimia/BED (MDMA-AT for trauma component) |
| Proposed mechanism | Ego dissolution interrupts rigid self-critical thinking; MDMA reduces threat response to underlying trauma memories |
| Availability | Clinical trials only — ClinicalTrials.gov is the legitimate source for enrolling trials |
| Timeline | Best-case availability 2028–2030, contingent on PTSD/depression approvals first |
Psychedelics and psychedelic therapy mostly associated with mental health issues such as anxiety, depression, and PTSD. But did you know both can potentially help treat eating disorders, too?
With new research, there’s incredible potential of psychedelic substances for other types of treatment methods. Addiction and eating disorders are conditions that many struggle with. Having psychedelic therapy as an option could make all the difference.
RELATED: Psychedelics For Eating Disorders: An Interview With Psychiatrist And Researcher Dr. Reid Robison
Eating Disorders 101
Eating disorders are serious illnesses associated with severe disturbances in eating behaviors, thoughts and emotions. They disrupt the relationship between food, body image, weight, and even exercise. This can severely impact one’s physical and mental health.
The most common eating disorders include anorexia nervosa, bulimia nervosa, and binge-eating disorder, all of which have descriptions below.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
Anorexia Nervosa
Anorexia Nervosa is a severe and sometimes fatal eating disorder. It leads to abnormally low weight, fear of food, and gaining weight. It also skews the perception of body image.
Those suffering from anorexia believe they’re overweight and live in fear of gaining weight if they consume food. Therefore, they often combine excessive exercise in an attempt to lose weight. They often avoid and restrict foods, and try to control their calorie intake. This may lead to vomiting after eating (crossover with bulimia), or by misusing laxatives, diet aids, diuretics or enemas.
Over time, the loss of nutrients can lead to malnutrition and severe health complications. These include negative effects on the heart, the inability to concentrate, memory issues, abdominal discomfort and pain, loss of period and irregular hormone levels, weakened bones and osteoporosis, among other issues.
Current treatments exist to stabilize weight loss and begin to restore and maintain adequate weight and nutrition. The hope is to restore a process of normalcy, and to develop long-term behavioral changes.
They mostly include some form of psychotherapy, as well as medications, mostly antipsychotics and SSRIs (antidepressants). Unfortunately, these options don’t work for everyone, and more people are searching for alternative methods to help long-term.
Bulimia Nervosa
Bulimia nervosa is similar to anorexia. It involves the fear of gaining weight and brings a distorted perception of one’s body shape and size. However, this involves eating large quantities of food, then vomiting in an attempt to lose ingested calories.
It can lead up to the same health complications as anorexia, but it can also have a severe impact on the digestive tract and gut lining. Current treatments once again include psychotherapy, antidepressants and antipsychotics, which more people find unsuccessful.
Binge-Eating Disorder
A binge-eating disorder usually involves eating large amounts of food to the point of severe overeating, followed by strict restriction. These cycles keep on repeating and causing an impaired relationship with food. It also impacts one’s perception of their own health and weight.
Unlike anorexia and bulimia — where the result usually ends in weight loss and really low BMI — those suffering from a binge-eating disorder may develop other complications. These include obesity, diabetes, and other gastro-intestinal, hormonal, or heart conditions. Current treatments include psychotherapy, mostly cognitive-behavioral therapy (CBT), and antidepressants or antipsychotics.
Psychedelic Therapy and Eating Disorders
Current treatment options from the most common eating disorders are all the same. That’s where psychedelic therapy comes in as an alternative.
The habitual pathways of communication between brain regions appear to be overactive in certain mental health conditions. These are often depression, anxiety, OCD and eating disorders. This is the brain’s default mode network (DMN). This connection may lead to the impairment of cognitive flexibility, which psychedelic therapy has shown to treat with great results.
The current, ongoing research shows impressive results from: Ketamine, MDMA, Psilocybin and Ayahuasca.
Ketamine as Psychedelic Therapy
In 1998, the first ketamine-assisted trial occurred, with infusions given to a group of 15 women suffering from extreme cases of anorexia nervosa. Nine of them eventually fell into remission. More than 20 years later, researchers are now aware of how this type of psychedelic therapy using ketamine can block compounds like glutamate and inhibit NMDA receptors. Both of these fuel anorexic thoughts and behaviors.
MDMA as Psychedelic Therapy
Currently, there are Phase 2 trials to discover if MDMA helps treat anorexia and other eating disorders. Researchers believe the psychedelic may aid in both recovery and potential remission. More info is necessary, but, at present, those conducting trials are optimistic about the outcome.
Psilocybin as Psychedelic Therapy
This form of psychedelic therapy is being studied as more than just an aid in treating depression, anxiety and PTSD. They are now on a path to help treat eating disorders as well and help those who really can’t seem to see any results from medications.
By increasing dopamine and serotonin to the brain, psilocybin therapy may be one of the best non-invasive ways to pair psychedelics with psychotherapy. The studies will show for themselves.
Ayahuasca as Psychedelic Therapy
Ayahuasca is also one of the psychedelics currently going through research as a potential alternative treatment for eating disorders. Participants often feel more distant from their behaviors, thought patterns and triggers. They also tend to notice a shift in attitude toward their bodies. It may be too early to draw conclusions, but these preliminary results only fuel optimism for further research.
Utilizing psychedelic therapy for eating disorders has shown early, positive results. However, more studies are necessary to determine if psychedelics are safe and an effective option.
Where The Research Stands in 2025
Since this article was first published, psychedelic-assisted therapy for eating disorders has moved from a theoretical framework to active clinical investigation. Several notable developments stand out.
Psilocybin for anorexia nervosa. Imperial College London and Johns Hopkins have both run pilot trials of psilocybin-assisted therapy specifically for anorexia nervosa — historically one of the most difficult mental health conditions to treat, with the highest mortality rate of any psychiatric disorder. Early results from these small trials (Phase 1/2, n=10–30) showed that psilocybin was well-tolerated, and a meaningful proportion of participants reported shifts in their relationship to food, body image, and the perfectionism that often underlies anorexia. These are not remission data — the sample sizes are too small — but they are sufficient to support larger trials now underway. One proposed mechanism is ego dissolution: psilocybin’s tendency to temporarily quiet the self-referential default mode network may interrupt the rigid self-critical thinking patterns that maintain disordered eating behaviors.
MDMA for trauma-driven eating disorders. A significant proportion of people with bulimia nervosa and binge eating disorder have histories of trauma. The clinical rationale for MDMA-assisted therapy in this population mirrors its use for PTSD: MDMA reduces the threat response to traumatic memories while enhancing therapeutic rapport, potentially allowing patients to revisit and reprocess experiences that drive disordered eating patterns. Formal trials of MDMA-AT for bulimia are still in early stages. The FDA’s rejection of the MAPS MDMA-AT PTSD application in 2024 (requesting additional Phase 3 data) has complicated but not ended the pipeline — eating disorder applications would follow successful PTSD approval.
What this means now. Psychedelic-assisted therapy for eating disorders is not yet available outside clinical trials. For people struggling with treatment-resistant anorexia, bulimia, or binge eating disorder, participating in a clinical trial is currently the only pathway to access. ClinicalTrials.gov lists active and recruiting trials. Standard of care — CBT, nutritional counseling, medication, residential treatment — remains the appropriate first-line approach while the research matures.
Frequently Asked Questions
Does psilocybin help with eating disorders?
Early-stage research is promising but not yet conclusive. Small pilot trials at Imperial College London and Johns Hopkins have shown that psilocybin-assisted therapy is safe in people with anorexia nervosa and produces measurable shifts in body image rigidity and self-critical thinking for a meaningful subset of participants. These are Phase 1/2 results with sample sizes of 10–30 people — they justify larger trials, which are now underway, but they are not sufficient to establish psilocybin as an evidence-based treatment. At this stage, psilocybin for eating disorders is a research-stage intervention, not a clinical option outside of trials.
Which eating disorders are being studied with psychedelic therapy?
Anorexia nervosa has been the primary focus of early psilocybin research, partly because standard treatments have limited effectiveness and the condition carries uniquely high mortality. Bulimia nervosa and binge eating disorder are being studied in the context of MDMA-assisted therapy, given the strong overlap between these conditions and trauma histories. Body dysmorphic disorder — which shares features with both OCD and eating disorders — has also been noted as a potential target for psilocybin. Researchers are still working out which specific eating disorder subtypes are likely to respond best to each psychedelic compound and therapeutic approach.
When will psychedelic therapy for eating disorders become available?
Realistically, not before the late 2020s at the earliest. Drug development timelines require Phase 2 and Phase 3 trials that may take 5–8 years to complete and analyze. Any FDA approval for psilocybin or MDMA for an eating disorder indication would follow successful PTSD and treatment-resistant depression approvals, which are themselves not yet finalized. The most optimistic scenario — fast-track designation, strong Phase 3 data, FDA approval — would put clinical availability in the 2028–2030 range. In the meantime, clinical trial participation is the only access pathway.
What should someone with an eating disorder know before considering a trial?
Anyone considering a psychedelic therapy trial for an eating disorder should discuss it thoroughly with their current treatment team first. Reputable trials have strict inclusion and exclusion criteria — most exclude people with active cardiovascular conditions, certain psychiatric diagnoses, or current medications that interact with the study drug. Trials are conducted under medical supervision with trained therapists and multiple safety checks. They are not a last resort to try without professional guidance. The primary resource for finding legitimate, IRB-approved trials is ClinicalTrials.gov — search for “psilocybin eating disorder” or “MDMA eating disorder.” Be cautious of retreat or wellness contexts presenting themselves as clinical research.
